PMID- 23584201
OWN - NLM
STAT- MEDLINE
DCOM- 20130610
LR  - 20211021
IS  - 1554-6578 (Electronic)
IS  - 0022-3069 (Print)
IS  - 0022-3069 (Linking)
VI  - 72
IP  - 5
DP  - 2013 May
TI  - A "weighted" fluorescence in situ hybridization strengthens the favorable 
      prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.
PG  - 432-41
LID - 10.1097/NEN.0b013e3182901f41 [doi]
AB  - Evaluation of the molecular status of 1p and 19q is a major relevant diagnostic, 
      prognostic, and predictive tool for oligodendroglial brain tumors. Fluorescence 
      in situ hybridization (FISH) is the most commonly used technique for determining 
      1p and 19q allelic losses, but it lacks fully standardized criteria for analysis. 
      This lack of standardization has led to interinstitutional disagreement in the 
      interpretation of results, thereby contributing to a "gray prognostic zone" that 
      includes codeleted patients with an unexpectedly unfavorable outcome. To optimize 
      the prognostic potential of 1p/19q status determination, we first compared the 
      actual criteria used for FISH reading (i.e. different ratio cutoff values and the 
      percentage of neoplastic nuclei carrying this chromosomal deletion) in a 
      retrospective series of 143 pure and mixed oligodendroglial tumors. We then 
      created a "weighted" FISH reading based on the merged ratio and percentage of 
      neoplastic cells carrying the deletion that was further differentially modulated 
      for 1p and 19q, respectively. This weighted codeletion setting significantly 
      strengthened the favorable prognostic power of 1p/19q losses by reducing the 
      number of poor outcomes from 42% to 12.5% for patients with codeleted tumors. 
      Thus, by identifying as codeleted only those cases with more than 50% of cells 
      having a combined loss of 1p (using 0.7 ratio cutoff) and 19q (using 0.8 ratio 
      cutoff) arms, we created a molecular report that bears higher clinical impact and 
      strengthens the prognostic potential of 1p/19q allelic loss.
FAU - Senetta, Rebecca
AU  - Senetta R
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Verdun di Cantogno, Ludovica
AU  - Verdun di Cantogno L
FAU - Chiusa, Luigi
AU  - Chiusa L
FAU - Castellano, Isabella
AU  - Castellano I
FAU - Gugliotta, Patrizia
AU  - Gugliotta P
FAU - Sapino, Anna
AU  - Sapino A
FAU - Cassoni, Paola
AU  - Cassoni P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neuropathol Exp Neurol
JT  - Journal of neuropathology and experimental neurology
JID - 2985192R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*diagnosis/*genetics
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Oligodendroglioma/*diagnosis/*genetics
MH  - Prognosis
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC3678883
COIS- The authors declare no conflicts of interest.
EDAT- 2013/04/16 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/16 06:00 [entrez]
PHST- 2013/04/16 06:00 [pubmed]
PHST- 2013/06/12 06:00 [medline]
AID - NEN20964 [pii]
AID - 10.1097/NEN.0b013e3182901f41 [doi]
PST - ppublish
SO  - J Neuropathol Exp Neurol. 2013 May;72(5):432-41. doi: 
      10.1097/NEN.0b013e3182901f41.